Earnings summaries and quarterly performance for MAIA Biotechnology.
Executive leadership at MAIA Biotechnology.
Board of directors at MAIA Biotechnology.
Research analysts covering MAIA Biotechnology.
Recent press releases and 8-K filings for MAIA.
MAIA Biotechnology Provides Update on Ateganosine Cancer Treatment Program and Outlines 2026 Milestones
MAIA
New Projects/Investments
Guidance Update
- MAIA Biotechnology secured FDA Fast Track designation for ateganosine in non-small cell lung cancer (NSCLC) and initiated a Phase 3 trial for third-line NSCLC patients in 2025.
- The company advanced its THIO-101 Phase 2 clinical trial to the Part C expansion phase, supported by a $2.3 million grant from the National Institutes of Health (NIH), and raised approximately $17.6 million from capital raises throughout 2025.
- Key milestones targeted for 2026 include initial efficacy measures from the Phase 3 study, conclusion of the Phase 2 Part C study, and continued regulatory interactions with the FDA, with potential for early commercial approval within 18 to 24 months.
3 days ago
MAIA Biotechnology Provides Update on Ateganosine Cancer Treatment Program and Outlines 2026 Milestones
MAIA
New Projects/Investments
Guidance Update
Capital Raises
- MAIA Biotechnology secured FDA Fast Track designation for ateganosine as a treatment for non-small cell lung cancer (NSCLC) and initiated a Phase 3 trial in 2025.
- The company anticipates a high probability of technical success in its pivotal Phase 3 trial, with potential for early commercial approval within 18 to 24 months.
- In 2025, MAIA raised approximately $17.6 million from capital raises.
- Key targeted 2026 milestones include expecting initial measures of efficacy from the Phase 3 study and the conclusion of Part C of the Phase 2 study.
3 days ago
MAIA Biotechnology Announces Private Placement and Phase 3 Trial Initiation
MAIA
New Projects/Investments
- MAIA Biotechnology raised $1.51 million through a private placement by issuing 1,233,488 common shares at $1.224 per share, each accompanied by a warrant, with independent directors participating to fund its Phase II THIO-101 trial and general working capital.
- The company initiated its pivotal Phase 3 THIO-104 trial for ateganosine in third-line non-small cell lung cancer (NSCLC), with the first patient dosed, building on promising Phase 2 data that demonstrated a median overall survival of 17.8 months.
- Ateganosine, which has Fast Track designation from the FDA, is positioned as a potential first-in-class telomere-targeting therapy to address a critical treatment gap in the advanced NSCLC market, projected to grow from $34 billion to $66 billion by 2032.
3 days ago
MAIA Biotechnology Directors Participate in Private Placement Offering
MAIA
New Projects/Investments
- MAIA Biotechnology announced that independent directors, including Adelina Louie Ngar Yee and Stan V. Smith, Ph.D., purchased common stock and warrants in a private placement offering that closed on December 22, 2025.
- Three directors collectively purchased 179,737 shares and 179,737 warrants at an average price of $1.224, generating gross proceeds of approximately $1.51 million.
- Directors and officers now hold a total of 5,019,857 shares, representing 13.43% of MAIA.
- This insider participation reflects strong confidence in ateganosine, MAIA's lead anticancer treatment for non-small cell lung cancer (NSCLC), for which a pivotal Phase 3 international trial was launched in December 2025.
Dec 24, 2025, 1:01 PM
MAIA Biotechnology Announces Private Placement
MAIA
Equity Offering
New Projects/Investments
- MAIA Biotechnology, Inc. announced a private placement on December 16, 2025, which is expected to close on or about December 18, 2025.
- The company will sell an aggregate of 1,233,488 shares of common stock at a purchase price of $1.224 per share, with each share offered together with a warrant to purchase one share of common stock at an exercise price of $1.36 per share.
- The gross proceeds from the offering are expected to be approximately $1.51 million.
- The net proceeds will be used to fund the execution of Step 1 of Part C of the Phase II trial THIO-101 and for working capital.
- The private placement includes participation from accredited investors and a Company director, with 179,737 shares and corresponding warrants issued to directors under the Company's 2021 Equity Incentive Plan.
Dec 17, 2025, 2:57 AM
MAIA Biotechnology Leadership Continues Insider Buying Amidst Encouraging Trial Data
MAIA
New Projects/Investments
- MAIA Biotechnology's CEO, Dr. Vlad Vitoc, and other board members acquired approximately 182,445 shares between November 21 and 28, 2025.
- This insider buying reflects confidence in the ateganosine platform, which is showing encouraging results in mid- to late-stage clinical development for advanced non-small cell lung cancer (NSCLC).
- Directors and Officers collectively hold 4,480,120 shares, representing 12.95% of the company.
Dec 11, 2025, 9:15 PM
MAIA Biotechnology Initiates Pivotal Phase 3 Trial for Ateganosine
MAIA
New Projects/Investments
- MAIA Biotechnology has initiated a pivotal Phase 3 program for its first-in-class telomere-targeting therapy, ateganosine (THIO), for advanced non-small cell lung cancer (NSCLC), with the Phase 2 trial still ongoing.
- Ateganosine is described as the only direct telomere-targeting anticancer agent currently in clinical development and has received U.S. FDA Fast Track designation for NSCLC.
- The therapy works through a dual mechanism of action that differentiates it from existing treatments, involving selective incorporation into cancer-cell telomeres and triggering an immunogenic response.
- Management indicates a very high probability of technical success for regulatory approval of ateganosine based on statistical assessments of the Phase 3 trial.
Dec 11, 2025, 6:00 PM
MAIA Biotechnology Reports Insider Share Purchases and Clinical Progress
MAIA
New Projects/Investments
- MAIA Biotechnology's CEO, Dr. Vlad Vitoc, and other board members acquired approximately 182,445 shares between November 21 and 28, 2025, demonstrating confidence in the company's ateganosine platform.
- The company's lead program, ateganosine, a telomere-targeting cancer therapy, is advancing through mid- to late-stage clinical development and continues to deliver encouraging results for non-small cell lung cancer (NSCLC).
- Directors and Officers of MAIA Biotechnology collectively hold 4,480,120 shares, representing 12.95% of the company.
Dec 11, 2025, 1:00 PM
MAIA Biotechnology Highlights Telomere-Targeting Agent Ateganosine and Market Opportunity
MAIA
New Projects/Investments
- MAIA Biotechnology is developing ateganosine, a potential first-in-class telomere-targeting agent for advanced non-small cell lung cancer (NSCLC) patients who are resistant to existing immunotherapies and chemotherapy.
- Ateganosine has received Fast Track Designation from the U.S. FDA for NSCLC and is initiating a Phase 3 THIO-104 trial.
- The NSCLC market is valued at $34.1 billion, projected to reach $68.8 billion by 2033, and ateganosine also holds FDA Orphan Drug Designations for Glioblastoma, Hepatocellular carcinoma, and Small cell lung cancer, offering seven years of U.S. market exclusivity upon regulatory approval.
Dec 10, 2025, 9:15 PM
MAIA Biotechnology Highlights Ateganosine Clinical Program Progress at SITC 2025
MAIA
New Projects/Investments
- MAIA Biotechnology highlighted the ongoing momentum of its Ateganosine clinical program at SITC 2025, covering Phase 2 THIO-101 and Phase 3 THIO-104 clinical trials for non-small cell lung cancer (NSCLC).
- The company reported 12 patients enrolled in the Phase 2 THIO-101 expansion trial, with enrollment expanding to European Medicines Agency countries, Turkey, and Taiwan.
- Patient screening has also begun for the Phase 3 THIO-104 trial.
- Ateganosine holds Fast Track designation from the U.S. FDA for NSCLC.
- The Phase 2 THIO-101 trial has demonstrated an overall survival (OS) of 17.8 months to date, compared to approximately 6 months for current third-line NSCLC treatments, with one patient showing survival of 30 months (912 days) as of September 17, 2025.
Nov 21, 2025, 2:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more